Host genetic influences on HIV-1 pathogenesis

Current Opinion in Immunology

Volumn 11, Issue 4, 1999, Pages 466-474

  Michael, Nelson L ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR;

GENETIC POLYMORPHISM; HLA SYSTEM; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENETICS; NONHUMAN; REVIEW; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS;

EID: 0033179134     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)80078-8     Document Type: Article

References (129)

1. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312:763-767.
2. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC, Montagnier L: T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312:767-768.
3. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986, 47:333-348.
4. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW: A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996, 85:1149-1158.
5. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA: The lymphocyte chemoattractant SDF-1 is a ligand for LESTER/fusin and blocks HIV-1 entry. Nature 1996, 382:829-832.
6. Berson JF, Long D, Doranz GJ, Rucker J, Jirik FR, Doms RW: A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 1996, 70:6288-6295.
7. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA: CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
8. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W et al.: The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85:1135-1148.
9. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
10. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA: HIV-1 entry in to CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
11. Feng Y, Broder C, Kennedy PE, Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996, 272:872-877.
12. Fenyo EM, Morfeldt ML, Chiodi F, Lind B, von Gegerfelt A, Albert J, Olausson E, Asjo B: Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolation. J Virol 1988, 62:4414-4419.
13. Tersmette M, Lang JMA, de Goede REY, de Wolf F, Eeftink-Schattenkerk JK, Schellekens PT, Coutinho RA, Huisman JG, Goudsmit J, Miedema F: Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989, 8645:983-985.
14. Berger EA, Doms RW, Fenyo E-M, Korber BTM, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA: A new classification for HIV-1. Nature 1998, 391:240.
15. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR: Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med 1997, 185:621-628.
16. Dittmar MT, McKnight A, Simmons G, Clapham PR, Weiss RA, Simmonds P: HIV-1 tropism and co-receptor use. Nature 1997, 385:495-496.
17. Chesebro B, Wehrly K, Nishio J, Perryman S: Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol 1996, 70:9055-9059.
18. Cheng-Mayer C, Liu R, Landau NR, Stamatatos L: Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J Virol 1997, 71:1657-1661.
19. Rana S, Besson G, Cook DG, Rucker J, Smyth RJ, Yi Y, Turner JD, Guo H-H, Du J-G, Peiper SC et al.: Role of CCR5 in infection of primary macrophages and lymphocytes by M-tropic strains of HIV: Resistance to patient-derived and prototype isolates resulting from the δccr5 mutation. J Virol 1997, 71:3219-3227.
20. He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, Busciglio J, Yang X, Hofmann W, Newman W et al.: CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997, 385:645-649.
21. Albright AV, Shieh JT, Itoh T, Lee B, Pleasure D, O'Connor MJ, Doms RW, Gonzalez-Scarano F: Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol 1999, 73:205-213. This paper describes the dominance of CCR5 as the HIV-1 entry coreceptor in tissues of the central nervous system. CCR3 and CXCR4 were shown to be minor coreceptors. Tissues were obtained from adults with AIDS dementia syndrome in distinction to He et al. [20] who used fetal tissues and demonstrated a more significant role for CCR3.
22. Sallusto F, Mackay CR, Lanzavecchia A: Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997, 277:2005-2007.
23. Gerber BO, Zanni MP, Uguccioni M, Loetscher M, Mackay CR, Pichler WJ, Yawalkar N, Baggiolini M, Moser B: Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol 1997, 7:836-843.
24. Zhang Y, Moore JP: Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J Virol 1999, 73:3443-3448. This paper convincingly demonstrated that coreceptor utilization assays performed using transduced cell lines do not always predict coreceptor utilization on primary human target cells. The dominance of CCR5 and CXCR4 as the major HIV-1 entry coreceptors was re-affirmed by the well-controlled experiments in this paper.
25. Zhang YJ, Dragic T, Cao Y, Kostrikis L, Kwon DS, Littman DR, Kewal-Ramani VN, Moore JP: Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J Virol 1998, 72:9337-9344.
26. Chen Z, Kwon D, Jin Z, Monard S, Telfer P, Jones MS, Lu CY, Aguilar RF, Ho DD, Marx PA: Natural infection of a homozygous delta24 CCR5 red-capped mangabey with an R2b-tropic simian immunodeficiency virus. J Exp Med 1998, 188:2057-2065. Marx and his team elegantly related geologic partitioning and subsequent speciation of West African mangabey monkeys associated with specific CCR2B polymorphisms to the evolution of phylogenetically distinct simian immunodeficiency viruses with radically different coreceptor utilization profiles.
27. Alkhatib G, Liao F, Berger EA, Farber JM, Peden KWC: A new SIV co-receptor, STRL33. Nature 1997, 388:238.
28. Deng H, Unutmaz D, Kewal-Ramani VN, Littman DR: Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997, 388:296-300.
29. Edinger AL, Hoffman TL, Sharron M, Lee B, O'Dowd B, Doms RW: Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins. Virology 1998, 249:367-378.
30. Loetscher M, Amara A, Oberlin E, Brass N, Legler D, Loetscher P, D'Apuzzo M, Meese E, Rousset D, Virelizier JL et al.: TYMSTR, a putative chemokine receptor selectively expressed in activated T cells, exhibits HIV-1 coreceptor function. Curr Biol 1997, 7:652-660.
31. Liao F, Alkhatib G, Peden KW, Sharma G, Berger EA, Farber JM: STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med 1997, 185:2015-2023.
32. Farzan M, Choe H, Martin K, Marcon L, Hofmann W, Karlsson G, Sun Y, Barrett P, Marchand N, Sullivan N et al.: Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med 1997, 186:405-411.
33. Rucker J, Edinger AL, Sharron M, Samson M, Lee B, Berson JF, Yi Y, Margulies B, Collman RG, Doranz BJ et al.: Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 1997, 71:8999-9007.
34. Horuk R, Hesselgesser J, Zhou Y, Faulds D, Halks-Miller M, Harvey S, Taub D, Samson M, Parmentier M, Rucker J et al.: The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J Biol Chem 1998, 273:386-391.
35. Pleskoff O, Treboute C, Alizon M: The cytomegalovirus-encoded chemokine receptor US28 can enhance cell-cell fusion mediated by different viral proteins. J Virol 1998, 72:6389-6397.
36. Choe H, Farzan M, Konkel M, Martin K, Sun Y, Marcon L, Cayabyab M, Berman M, Dorf ME, Gerard N et al.: The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1. J Virol 1998, 72:6113-6118.
37. Edinger AL, Hoffman TL, Sharron M, Lee B, Yi Y, Choe W, Kolson DL, Mitrovic B, Zhou Y, Faulds D et al.: An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 1998, 72:7934-7940.
38. Samson M, Edinger AL, Stordeur P, Rucker J, Verhasselt V, Sharron M, Govaerts C, Mollereau C, Vassart G, Doms RW, Parmentier M: ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur J Immunol 1998, 28:1689-1700.
39. Owman C, Garzino-Demo A, Cocchi F, Popovic M, Sabirsh A, Gallo RC: The leukotriene B4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. Proc Natl Acad Sci USA 1998, 95:9530-9534.
40. Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF: Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1β, and MIP-1α. J Biol Chem 1996, 271:17161-17166.
41. Sampson M, Labbe O, Mollereau C, Vassart G, Parmentier M: Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996, 35:3362-3367.
42. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier J-L, Arenzana-Seisdedos F, Schwartz O, Heard J-M, Clark-Lewis I, Legier DF et al.: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996, 382:833-835.
43. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, Choe H, Sodroski J, Newman W, Koup RA, Mackay CR: CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997, 185:1681-1691.
44. Jansson M, Popovic M, Karlsson A, Cocchi F, Rossi P, Albert J, Wigzell H: Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci USA 1996, 93:15382-15387.
45. + T cells. Science 1995, 270:1811-1815.
46. Cocchi F, De Vico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P: The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 1996, 2:1244-1247.
47. Farzan M, Choe H, Martin KA, Sun Y, Sidelko M, Mackay CR, Gerard NP, Sodroski J, Gerard C: HIV-1 entry and macrophage inflammatory protein-1 beta-mediated signaling are independent functions of the chemokine receptor CCR5. J Biol Chem 1997, 272:6854-6857.
48. Gosling J, Monteclaro FS, Atchinson RE, Arai H, Tsou C-L, Goldsmith MA, Charo IF: Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proc Natl Acad Sci USA 1997, 94:5061-5066.
49. Atchison RE, Gosling J, Monteclaro FS, Franci C, Digilio L, Charo IF, Goldsmith MA: Multiple extracellular elements of CCR5 and HIV-1 entry: Dissociation from response to chemokines. Science 1996, 274:1924-1926.
50. Sampson M, Libert F, Doranz BL, Rucker J, Liesnard C, Farber C-M, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C et al.: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
51. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
52. + T lymphocytes from two multiply exposed, uninfected individuals resist infection with primary non-syncytium-inducing isolates of human immunodeficiency virus type 1. J Virol 1996, 70:8758-8764.
53. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter NL, Padian N, Braun JF, Kotler DP, Wolinsky SM, Koup RA: Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high risk exposures. Nat Med 1996, 2:412-417.
54. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Haemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862.
55. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K et al.: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996, 2:1240-1243.
56. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, Sheppard HW: The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997, 3:338-340.
57. Eugen-Olsen J, Iversen AKN, Garred P, Koppelhus U, Pedersen C, Benfield TL, Sorensen AM, Katzenstein T, Dickmeiss E, Gerstoft J et al.: Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997, 11:305-310.
58. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, Weissman D, Cohen O, Rubbert A, Lam G et al.: Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: Studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997, 3:23-36.
59. Paxton WA, Kang S, Koup RA: The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression. AIDS Res Hum Retroviruses 1998, 14:S89-S92. This paper confirmed the association of the CCR5Δ32 allele with reduced HIV-1 transmission risk and delayed disease progression in a large cohort of homosexual males.
60. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T: HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997, 3:252-253.
61. O'Brien TR, Winkler C, Dean M, Nelson JA, Carrington M, Michael NL, White GC II: HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 1997, 349:1219.
62. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C: HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet 1997, 349:1219-1220.
63. Balotta C, Bagnarelli P, Violin M, Ridolfo AL, Zhou D, Berlusconi A, Corvasce S, Corbellino M, Clementi M, Clerici M et al.: Homozygous 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 1997, 11 :F67-F71.
64. Heiken H, Bastisch I, Schmidt RE: HIV-1 infection in a heterosexual man homozygous for CCR-5δ32. AIDS 1999, 13:529-530.
65. Kuipers H, Workman C, Dyer W, Geczy A, Sullivan J, Oelrichs R: An HIV-1 infected individual homozygous for the CCR-5 δ32 allele and the SDF-1 3′A allele. AIDS 1999, 13:433-434.
66. Goh WC, Markee J, Akridge RE, Meldorf M, Musey L, Karchmer T, Krone M, Collier A, Corey L, Emerman M, McElrath MJ: Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: Evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis 1999, 179:548-557.
67. Michael NL, Nelson JA, Kewal-Ramani VN, Chang G, O'Brien SJ, Mascola JR, Volsky B, Louder M, White GC II, Littman DR et al.: Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol 1998, 72:6040-6047. This first characterization of HIV-1 coreceptor utilization from an individual homozygous for the CCR5Δ32 allele revealed restriction to CXCR4 without 'minor HIV-1 coreceptor' utilization, calling into question the physiologic relevance of these proteins and it demonstrated that persistent CXCR4 usage is not uniformly associated with accelerated disease progression.
68. Richman DD, Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994, 169:968-974.
69. Michael NL, Moore JP: HIV-1 entry inhibitors: evading the issue. Nat Med 1999, 5:740-742.
70. Edelstein RE, Arcuino LA, Hughes JP, Melvin AJ, Mohan KM, King PD, McLellan CL, Murante BL, Kassman BP, Frenkel LM: Risk of mother-to-infant transmission of HIV-1 is not reduced in CCR5/delta32ccr5 heterozygotes. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:243-246.
71. Malo A, Rommel F, Bogner J, Gruber R, Schramm W, Goebel FD, Riethmuller G, Wank R: Lack of protection from HIV infection by the mutant HIV coreceptor CCR5 in intravenously HIV infected hemophilia patients. Immunobiology 1998, 198:485-488.
72. Mangano A, Prada F, Roldan A, Picchio G, Bologna R, Sen L: Distribution of CCR-5 delta32 allele in Argentinian children at risk of HIV-1 infection: Its role in vertical transmission. AIDS 1998, 12:109-110.
73. Misrahi M, Teglas JP, N'Go N, Burgard M, Mayaux MJ, Rouzioux C, Delfraissy JF, Blanche S: CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. French Pediatric HIV Infection Study Group. JAMA 1998, 279:277-280.
74. Rousseau CM, Just JJ, Abrams EJ, Casabona J, Stein Z, King MC: CCR5del32 in perinatal HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:239-242.
75. Shearer WT, Kalish LA, Zimmerman PA: CCR5 HIV-1 vertical transmission. Women and Infants Transmission Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 17:180-181.
76. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, Craig FE, O'Connell P, Tryon V, Clark RA et al.: Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998, 4:786-793. Mummidi et al. confirmed the association of CCR2B64I with delayed disease progression in African-American, but not Caucasian, US military personnel but found no such association with CCR5Δ32. In distinct contrast to [115•], they found and association of SDF-1 3′A with accelerated, not delayed, disease progression. CCR5 promoter polymorphisms were described but without clear association with pathogenesis.
77. Hoffman TL, MacGregor RR, Burger H, Mick R, Doms RW, Collman RG: CCR5 genotypes in sexually active couples discordant for human immunodeficiency virus type 1 infection status. J Infect Dis 1997, 176:1093-1096.
78. Mandl CW, Aberle SW, Henkel JH, Puchhammer-Stockl E, Heinz FX: Possible influence of the mutant CCR5 allele on vertical transmission of HIV-1. J Med Virol 1998, 55:51-55.
79. Martinson JJ, Chapman NH, Rees DC, Liu Y-T, Clegg JB: Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997, 16:100-103.
80. Libert F, Cochaus P, Beckman G, Samson M, Aksenova M, Cao A, Czeizel A, Claustres M, de la Rua C, Ferrari M et al.: The δCCR5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in northeast Europe. Hum Mol Genet 1998, 7:399-406. These two papers [80•,81•] present lines of evidence for the recent fixation of the CCR5Δ32 allele in Caucasian populations in Northwest Europe around the time of the fourteenth Century bubonic plague epidemic. The fascinating - but unproven - theory suggests that the CCR5Δ32 allele provided a selective advantage for individuals exposed to the etiologic agent of plague, Yersinia pestis.
81. Stephens JC, Reich DE, Goldstein DB, Shin HD, Smith MW, Carrington M, Winkler C, Huttley GA, Allikmets R, Schriml L et al.: Dating the origin of the CCR5-δ32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 1998, 62:1507-1515. See annotation [80•].
82. Rappaport J, Cho YY, Hendel H, Schwartz EJ, Schachter F, Zagury JF: 32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes. Lancet 1997, 349:922-923.
83. Katzenstein TL, Eugen-Olsen J, Hofman B, Benfield T, Pedersen C, Iversen AKN, Sorensen AM, Garred P, Koppelus U, Svejgaard A, Gerstoft J: HIV-1 infected individuals with the CCR5δ32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:10-14.
84. Morawetz RA, Rizzardi GP, Glauser D, Rutschmann O, Hirschel B, Perrin L, Opravil M, Flepp M, Overbeck J, Glauser MP et al.: Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5/δccr5) genotype is neither essential nor sufficient for protection against disease progression. Eur J Immunol 1997, 12:3223-3227.
85. Wilkinson DA, Operskalski EA, Busch MP, Mosley JW, Koup RA: A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness. J Infect Dis 1998, 178:1163-1166.
86. Schinkel J, Langendam MW, Coutinho RA, Krol A, Brouwer M, Schuitemaker H: No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. J Infect Dis 1999, 179:825-831.
87. Paxton WA, Liu R, Kang S, Wu L, Gingeras TR, Landau NR, Mackay CR, Koup RA: Reduced HIV-1 infectibility of CD4+ lymphocytes from exposed-uninfected individuals: Association with low expression of CCR5 and high production of β-chemokines. Virology 1998, 244:66-73.
88. Michael NL, Louie LG, Rohrbaugh AL, Schultz KA, Dayhoff DE, Wang CE, Sheppard HW: The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997, 3:1160-1162.
89. de Roda Husman A-M, Koot M, Cornelissen M, Keet IPM, Brouwer M, Broersen S, Bakker M, Roos MTL, Prins M, de Wolf F et al.: The association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Int Med 1997, 127:882-890.
90. Bratt G, Leandersson A-C, Albert J, Sandstrom E, Wahren B: MT-2 tropism and CCR5 genotype strongly influence disease progression in HIV-1 infected individuals. AIDS 1998, 12:729-736. These authors confirmed the dominant association of the CCR5Δ32 allele with delayed disease progression in individuals whose HIV-1 primarily utilized CCR5 and not CXCR4 as originally proposed in [88,89].
91. Buseyne F, Janvier G, Teglas JP, Ivanoff S, Burgard M, Bui E, Mayaux MJ, Blanche S, Rouzioux C, Riviere Y: Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age. J Infect Dis 1998, 178:1019-1023.
92. Quillent C, Oberlin E, Braun J, Rousset D, Gonzalez-Canali G, Metais P, Montagnier L, Virelizier JL, Arenzana-Seisdedos F, Beretta A: HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998, 351:14-18. A single individual resistant to R5 HIV-1 was reported who carried a single allele each of CCR5Δ32 and a rarer CCRS-inactivating polymorphism termed CCR5m303. This observation is sentinel to other, as yet undiscovered, genetic associations with HIV pathogenesis.
93. Carrington M, Kissner T, Gerrard B, Ivanov S, O'Brien SJ, Dean M: Novel allele of the chemokine-receptor gene CCR5. Amer J Hum Genet 1997, 61:1261-1267.
94. Ansari-Lari MA, Liu X-M, Metzker ML, Rut AR, Gibbs RA: The extent of genetic varitation in the CCR5 gene. Nat Genet 1997, 16:221-222.
95. Martin MP, Carrington M, Dean M, O'Brien SJ, Sheppard HW, Wegner SA, Michael NL: CXCR4 polymorphisms and HIV-1 pathogenesis. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:430. The virtual lack of genetic polymorphisms in the entire CXCR4 transcription unit was demonstrated in a large group of HIV-1-infected individuals with divergent rates of HIV disease progression and HIV-1-uninfected individuals with variable risk behaviors for HIV transmission. These data underscore the more central role for CXCR4 in normal human physiology compared with CCR5 and may predict greater clinical toxicity with pharmacological inhibition of the former receptor.
96. Wegner SA, Ehrenberg PK, Chang G, Dayhoff DE, Sleeker AL, Michael NL: Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. J Biol Chem 1998, 273:4754-4760.
97. Cohen OJ, Paolucci S, Bende SM, Daucher M, Moriuchi H, Moriuchi M, Cicala C, Davey RT Jr, Baird B, Fauci AS: CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: Lack of association with mutations other than CCR5-Delta32. J Virol 1998, 72:6215-6217.
98. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.
99. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T: Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996, 382:635-638.
100. Loetscher M, Geiser T, O'Reilly T, Zwahlen R, Baggiolini M, Moser B: Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J Biol Chem 1994, 269:232-237.
101. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobsen LP, Kaslow R et al.: Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Haemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort, ALIVE Study. Science 1997, 277:959-965.
102. Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, Zhang L, Guo Y, Deutch L, Phair J, Neumann AU, Ho DD: A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998, 4:350-353. Kostrikis et al. confirmed the association of the CCR2B64I allele with delayed disease progression in seroincident (duration of HIV infection more precisely known) but not seroprevalent (duration of HIV infection less certain) cohorts, providing a plausible explanation for the disparate conclusions of [88] and [101].
103. Hendel H, Henon N, Lebuanec H, Lachgar A, Poncelet H, Caillat-Zucman S, Winkler CA, Smith MW, Kenefic L, O'Brien S et al.: Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:381-386.
104. Rizzardi GP, Morawetz RA, Vicenzi E, Ghezzi S, Poli G, Lazzarin A, Pantaleo G: CCR2 polymorphism and HIV disease. Swiss HIV Cohort. Nat Med 1998, 4:252-253.
105. Eugen-Olsen J, Iversen AKN, Benfield TL, Koppelhus U, Garred P: Chemokine receptor CCR2b 64I polymorphism and its relation to CD4 counts and disease progression in a Danish cohort of HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:110-116.
106. Ioannidis JPA, O'Brien TR, Rosenberg PS, Contopoulos-Ioannidis DG, Goedert JJ: Genetic effects on HIV disease progression. Nat Med 1998, 4:536-537. The first results of a formal meta-analysis of the association of the CCR5Δ32 and CCR2B64I alleles with delayed HIV disease progression confirmed both associations but demonstrated a more statistically robust association for CCR5Δ32. This publication has since spawned an impressive international collaboration between the authors and virtually every group that has contributed to this literature. This far-sighted process will undoubtedly be the final word for the association of genetic polymorphisms with HIV pathogenesis.
107. Mariani R, Wong S, Mulder LCF, Wilkenson D, Reinhart AL, LaRosa G, Nibbs R, Michael NL, Connor RI, MAcdonald M et al.: The CCR2-64I polymorphism is not associated with altered CCR5 expression, coreceptor function or HIV-1 replication. J Virol 1999, 73:2450-2459. See annotation [108•].
108. Lee B, Doranz BJ, Rana S, Yi Y, Mellado M, Frade JM, Martinez AC, O'Brien SJ, Dean M, Collman RG, Doms RW: Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol 1998, 72:7450-7458. These papers [107•,108•] collectively provide evidence for the lack of association of CCR2B64I with CCR2B coreceptor activity, expression of CCR2B, CCR5 or CXCR4 and susceptibility to infection with R5 or X4 HIV-1. Subtle associations of CCR2B ligand binding with subsequent attenuated responsiveness of CCR5 and CXCR4 to their cognate ligands were reported by Lee et al. [108•].
109. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM: CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998, 352:866-870. These papers [109••,110••] describe CCR5 promoter polymorphisms that are associated with accelerated HIV disease progression in the absence of the moderating influence of so-called 'protective' alleles such as CCR5Δ32, CCR2B64I or SDF-1 3′A. Although McDermott et al. [109••] suggested an association of the disease-accelerating CCR5 promoter allele with increased CCR5 promoter activity in a neoplastic cell line model, Martin et al. [110••] could demonstrate no association with CCR5 or CXCR4 expression nor susceptibility to HIV-1 infection in primary human T cells.
110. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, Lee B, Doms RW, Margolick J, Buchbinder S et al.: Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998, 282:1907-1911. See annotation [109••].
111. Guignard F, Combadiere C, Tiffany HL, Murphy PM: Gene organization and promoter function for CC chemokine receptor 5 (CCR5). J Immunol 1998, 160:985-992.
112. Moriuchi H, Moriuchi M, Fauci AS: Cloning and analysis of the promoter region of CCR5, a coreceptor for HIV-1 entry. J Immunol 1997, 159:5441-5449.
113. Liu R, Zhao X, Gurney TA, Landau NR: Functional analysis of the proximal CCR5 promoter. AIDS Res Hum Retroviruses 1998, 14:1509-1519.
114. Mummidi S, Ahuja SS, McDaniel BL, Ahuja SK: The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts with 5′-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons. J Biol Chem 1997, 272:30662-30671.
115. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D et al.: Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998, 279:389-393. Winkler et al. first described the SDF-1 3′A allele and its association with delayed disease progression in this large study of multiple HIV infected cohorts.
116. Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T, Honjo T: Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics 1995, 28:495-500.
117. van Rij RP, Broersen S, Goudsmit J, Coutinho RA, Scuitemaker H: The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 1998, 12:F85-F90. van Rij et al., in agreement with [76•], demonstrated an association of SDF-1 3′A with accelerated - not delayed - disease progression as reported by Winkler et al. [115•]. These results underscore the need for the formal meta-analysis program described in [106••].
118. Dupont B: Immuobiology of HLA. New York: Springer-Verlag; 1986.
119. Parham P, Ohta T: Population biology of antigen presentation by MHC class I molecules. Science 1996, 272:67-74.
120. Hughes AL, Yeager M: Natural selection at major histocompatibility complex loci of vertebrates. Annu Rev Genet 1998, 32:415-435. This review delineates the impressive evidence for selective forces acting at the MHC, which controls the presentation of peptides to the immune system.
121. Zinkernagel RM, Hengartner H: Correlates of protective viruses damaging to HIV infection. Science 1996, 272:1362.
122. Doherty PC, Zinkernagel RM: Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex. Nature 1975, 256:50-52.
123. Gilbert SC, Plebanski M, Gupta S, Morris J, Cox M, Aidoo M, Kwiatkowski D, Greenwood BM, Whittle HC, Hill AV: Association of malaria parasite population structure, HLA, and immunological antagonism. Science 1998, 279:1173-1177.
124. Thursz MR, Kwiatkowski D, Allsopp CE, Greenwood BM, Thomas HC, Hill AV: Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995, 332:1065-1069.
125. Thursz MR, Thomas HC, Greenwood BM, Hill AV: Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet 1997, 17:11-12. [Published erratum appears in Nat Genet 1998, 18:88.]
126. Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, Bennett S, Brewster D, McMichael AJ, Greenwood BM: Common West African HLA antigens are associated with protection from severe malaria. Nature 1991, 352:595-600.
127. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinders, Hoots K, O'Brien SJ: HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999, 283:1748-1752. Carrington et al. definitively demonstrate the association of HLA alleles B35 and Cw4 with accelerated disease progression. This paper is notable for its rigor in confirming the specificity of the former observation to the HLA locus itself and not just to the general region of the human genome in which it resides.
128. Bruunsgaard H, Pedersen C, Skinhoj P, Pedersen BK: Clinical progression of HIV infection: Role of NK cells. Scand J Immunol 1997, 46:91-95.
129. Magierowska M, Theodorou I, Debre P, Sanson F, Autran B, Riviere Y, Charron D, Costagliola D: Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood 1999, 93:936-941.